DRAP (Pakistan)

The Drug Regulatory Authority of Pakistan (DRAP — ڈرگ ریگولیٹری اتھارٹی آف پاکستان) — operating as autonomous federal authority attached to the Ministry of National Health Services, Regulations and Coordination (M/o NHSR&C) — is the Islamic Republic of Pakistan's national regulatory authority for human + veterinary medicines + biologicals + biosimilars + vaccines + medical devices + IVDs + alternative medicines + health products + nutraceuticals + cosmetics + therapeutic goods + pharmacy practice + controlled substances + clinical trials. DRAP was established under the DRAP Act 2012 (replacing the prior Drug Controller framework under the Drugs Act 1976) + operates the Drugs Act 1976 + Pakistan Pharmacy Act 1967 + Alternative Medicines + Health Products Rules 2014 + Medical Devices Rules 2017 + Biological Drugs Rules 2022 + Pharmacovigilance Rules 2022 + DRAP General Rules 2014 + Drug Pricing Policy 2018 (amended) + Controlled Drugs Act 1979.

DRAP organisational structure includes:

• Federal Minister for National Health Services, Regulations and Coordination — political head; appointed by the Prime Minister.
• Chief Executive Officer of DRAP — DRAP head; appointed by the Federal Government under DRAP Act 2012 Section 7.
• DRAP Policy Board — comprising provincial + federal + professional representatives providing policy direction.
• Authority — comprising CEO + 11 Directors heading 11 functional Divisions.
• Division of Pharmaceutical Evaluations and Registration — drug + biological + biosimilar + vaccine registration including Registration Board + Expert Committees.
• Division of Quality Assurance and Lab Testing — Central Drugs Laboratory Karachi + Central Drugs Laboratory Islamabad + National Control Laboratory for Biologicals (NCLB) Islamabad.
• Division of Pharmacy Services — pharmacy practice + pharmaceutical-establishment licensing.
• Division of Drug Licensing — manufacturing + import + distribution licensing.
• Division of Health and OTC Products — alternative medicines + nutraceuticals + health products + OTC framework.
• Division of Medical Devices and Medicated Cosmetics — medical-device + IVD + medicated-cosmetics registration substantively aligned with EU MDR + IVDR + IMDRF elements.
• Division of Costing and Pricing — Drug Pricing Policy + reference-pricing + MRP-fixation framework.
• Division of Biological Drugs — biological + biosimilar + vaccine + plasma-derived medicinal products framework.
• Division of Controlled Drugs — narcotics + psychotropics framework coordination with INCB + Anti-Narcotics Force + Pakistan Customs.
• Division of Pharmacovigilance and Clinical Studies — Pakistan National Pharmacovigilance Centre + CTA + Ethics Committee + IRB coordination.
• Division of Budget, Accounts and Administration — administrative + financial-services support.
• Regional + Provincial Inspectorate Field Offices — Karachi + Lahore + Peshawar + Quetta + Multan + Hyderabad + Faisalabad + Rawalpindi + substantial provincial inspectorate operations.

Pakistan's distinctive South Asian + Islamic regional pharmaceutical-hub context: Pakistan is one of the largest + most operationally significant South Asian pharmaceutical regulators by population + manufacturing-base + export-volume measures. The Islamic Republic of Pakistan is the world's 5th-most-populous country (~241 million) + one of the largest Muslim-majority countries with substantial regional pharmaceutical-manufacturing hub status: ~700+ Pakistani-domestic manufacturers + ~800+ pharmaceutical-manufacturing facilities covering ~80% of domestic consumption by volume + substantial export industry to ~140+ countries reaching ~USD 350+ million annual export value notably Getz Pharma + Hilton Pharma + Searle + Sami Pharma + GlaxoSmithKline Pakistan + Abbott Pakistan + Highnoon Laboratories + Pharmevo + Macter International + Bosch Pharmaceuticals + Nabiqasim Industries + ICI Pakistan + Atco Laboratories + Helix Pharma + Bryon Pharmaceuticals + Wilson's Pharmaceuticals + Pakistan National Institute of Health + National Institute of Health Islamabad + Vaccine Institute substantial vaccine + biological capacity. Pakistan has substantial vaccine-manufacturing capacity via NIH Islamabad (anti-rabies + DPT + TT + measles + cholera + typhoid vaccines historically) + private-sector partnerships. Pakistan is uniquely positioned by substantial China-Pakistan Economic Corridor (CPEC) Belt and Road Initiative pharmaceutical + API + medical-device trade growth + substantial Gulf export-market position (Saudi Arabia + UAE + Qatar + Oman + Bahrain + Kuwait + Iraq + Yemen) + substantial sub-Saharan African + Central Asian + South-East Asian export-market position + substantial halal-pharmaceutical + halal-cosmetics certification capacity. Pakistan's geographic + economic position at the crossroads of South Asia + Central Asia + Middle East + China makes it operationally significant for foreign manufacturers + sponsors targeting SAARC + Gulf + Central Asian + sub-Saharan African halal markets via Pakistan-localised manufacturing.

DRAP is distinct from + complementary to: the Pakistan Pharmacists Association (professional licensing body for individual pharmacists); the Pakistan Medical Commission (physician + dental + healthcare-professional licensing); the Pakistan Pharmaceutical Manufacturers Association (PPMA — representing manufacturers); Anti-Narcotics Force (ANF — narcotics enforcement); Pakistan Customs (import-export control); provincial Health Departments (Punjab + Sindh + Khyber Pakhtunkhwa + Balochistan + AJK + GB Health Secretaries operating provincial healthcare-delivery + drug-inspection); Pakistan Council for Scientific and Industrial Research (PCSIR — pharmaceutical research); Pakistan Atomic Energy Commission (PAEC — substantial radiopharmaceutical + nuclear-medicine capacity); Aga Khan University + Karachi University + Punjab University + Quaid-i-Azam University + COMSATS substantial pharmaceutical-research + clinical-research capacity. Pakistan's pharmaceutical environment is uniquely characterised by: substantial regional pharmaceutical-manufacturing hub status with ~80% domestic-volume self-sufficiency; substantial export industry to ~140+ countries; substantial Gulf + Central Asian + sub-Saharan African halal-pharmaceutical export-market position; substantial CPEC + Belt and Road pharmaceutical + API + medical-device trade growth; PIC/S Member status (since 2024); substantial WHO PQ programme participation; substantial Drug Pricing Policy 2018 (amended) operational framework; substantial alternative-medicine industry (Unani + Ayurvedic + Homeopathic + Herbal + Biochemic — distinctive cultural-pharmaceutical context); Urdu + English overlay labelling; substantial Climate Zone IVa Indo-Gangetic Plain + IVb arid Thar + Balochistan + monsoon-affected coastal Karachi + Gwadar + Himalayan high-altitude Northern Areas stability requirements.

DRAP is a PIC/S Member (since 2024) + WHO PIDM Member + WHO PQ programme participant + ECO Member State + WHO SEARO/EMRO observer + ICH Observer + maintains substantial bilateral cooperation with Indian CDSCO (cross-border South Asian SAARC peer) + Chinese NMPA (CPEC Belt and Road substantial bilateral cooperation) + Turkish TİTCK (regional ECO + PIC/S Member peer) + Iranian IFDA (ECO + regional border peer) + Afghan MoPH (substantial humanitarian + bilateral cooperation) + Bangladeshi DGDA + Sri Lankan NMRA (SAARC peers) + Saudi SFDA + UAE MoHAP + GCC regulators (substantial Gulf-export market + GHC reliance) + UK MHRA + EMA + WHO + UNICEF + Gavi + Global Fund + Stop TB Partnership reflecting Pakistan's strategic regional + global pharmaceutical-trade position.

Pakistani pharmaceutical regulation operates under a layered framework of Acts + Rules + DRAP General Rules + DRAP Guidelines — incorporating substantial PIC/S GMP + ICH guideline + WHO TRS Annex elements:

• DRAP Act 2012 — DRAP establishment as autonomous federal authority + governance + functional framework.
• Drugs Act 1976 — foundational pharmaceutical law for human + veterinary drugs + therapeutic substances.
• Pakistan Pharmacy Act 1967 — pharmacy practice + pharmacist licensing framework.
• Alternative Medicines + Health Products Rules 2014 — distinctive Unani + Ayurvedic + Homeopathic + Herbal + Biochemic + nutraceutical + health-product framework.
• Medical Devices Rules 2017 — substantively incorporating EU MDR + IVDR + IMDRF elements.
• Biological Drugs Rules 2022 — biological + biosimilar + vaccine + plasma-derived medicinal products framework substantively aligned with WHO + EMA + WHO PQ biosimilar guidance.
• Pharmacovigilance Rules 2022 — substantively aligned with ICH E2 + WHO PV guidance + EU GVP elements.
• DRAP General Rules 2014 — implementing rules covering registration + GMP + GDP + GPP + variations.
• Drug Pricing Policy 2018 (amended) — substantive pricing-control framework including MRP fixation + Reference Pricing + Hardship Cases + Annual CPI-linked adjustment + Innovative Drug pricing.
• Controlled Drugs Act 1979 — narcotics + psychotropics + precursors framework.
• DRAP GMP Guide — substantively aligned with PIC/S GMP Guide + ICH Q7 + WHO TRS 986 Annex 2 + EU GMP elements.
• DRAP GDP Guide — substantively aligned with WHO GDP + EU GDP elements.
• DRAP GCP Guide — substantively aligned with ICH E6(R2).
• DRAP GVP Guide — substantively aligned with ICH E2 + WHO PV guidance + EU GVP elements.
• Pharmacopoeia recognition — recognises British Pharmacopoeia + USP + European Pharmacopoeia + International Pharmacopoeia + Indian Pharmacopoeia.
• Pakistan National Essential Medicines List (NEML) — substantively aligned with WHO Essential Medicines List + Provincial Essential Medicines Lists.
• Variations + 5-year Registration Renewal framework.
• Halal Pharmaceuticals + Halal Cosmetics Framework — distinctive halal-certification framework via Pakistan Halal Authority + provincial Halal Authorities + Pakistan Standards and Quality Control Authority (PSQCA) coordination supporting substantial Gulf + Central Asian + Indonesian + Malaysian + Brunei + sub-Saharan African halal-pharmaceutical export-market access.

DRAP operates the Central Drugs Laboratory Karachi (CDL-Karachi) + Central Drugs Laboratory Islamabad (CDL-Islamabad) + National Control Laboratory for Biologicals (NCLB) Islamabad — substantial vaccine + biological lot-release capacity. DRAP is a PIC/S Member (since 2024) enabling substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections. The DRAP Division of Quality Assurance and Lab Testing conducts substantial inspections of Pakistani-domestic + foreign manufacturing facilities both domestically + via PIC/S mutual-recognition + bilateral arrangements.

• ISO/IEC 17025 — DRAP CDL-Karachi + CDL-Islamabad + NCLB operate with substantial ISO/IEC 17025 accredited scope.
• WHO PQ-Lab — NCLB Islamabad + CDL-Karachi WHO PQ-Lab aspiration via WHO + bilateral-donor capacity expansion.
• PIC/S Member (since 2024) — substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections; one of the most operationally significant DRAP capabilities for foreign-manufacturer GMP-inspection coordination + Pakistani-domestic manufacturer export-market support.
• Vaccine lot release — NCLB Islamabad substantial vaccine lot-release testing for Pakistan Expanded Programme on Immunization (EPI) + substantial Pakistani-domestic vaccine-manufacturing capacity + WHO PQ programme.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + substantial post-market surveillance + targeted enforcement testing.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Alternative-medicine + nutraceutical + health-product testing — distinctive Unani + Ayurvedic + Homeopathic + Herbal + Biochemic + nutraceutical + health-product safety + ingredient compliance testing.
• Counterfeit-medicine forensics — substantial forensic analytical support for DRAP + ANF + Pakistan Customs + WHO Global Surveillance & Monitoring System contributions; substantial counterfeit-medicine quality risk given regional cross-border smuggling + substantial pharmaceutical supply-chain complexity.
• Substantial export-market support — DRAP provides substantial Pakistani-domestic manufacturer export-market support to ~140+ countries via GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product + WHO CPP issuance reaching ~USD 350+ million annual export value.
• Capacity-building — substantial WHO + bilateral-donor capacity-building programmes + training for Pakistani pharmaceutical analysts including Pakistan Council for Scientific and Industrial Research (PCSIR) + Pakistan National Institute of Health partnerships.
• GMP Inspectorate — substantial PIC/S Member capability for Pakistani + foreign manufacturing facility GMP inspections both domestically + via PIC/S mutual-recognition + bilateral arrangements; substantial export-market support for ~700+ Pakistani-domestic manufacturers.
• Halal-pharmaceutical + halal-cosmetics certification support — distinctive halal-certification analytical capacity supporting substantial Gulf + Central Asian + Indonesian + Malaysian + Brunei + sub-Saharan African halal-pharmaceutical export-market access via Pakistan Halal Authority + PSQCA coordination.

DRAP medical-device + IVD regulation operates under Medical Devices Rules 2017 substantively incorporating EU MDR 2017/745 + IVDR 2017/746 + IMDRF elements. Pakistan has growing medical-device-manufacturing capacity with ~150+ Pakistani-domestic medical-device manufacturers covering substantial portions of domestic consumption + regional Gulf + Central Asian + sub-Saharan African export markets.

• Risk-based Classification (Class A / B / C / D) — substantively aligned with EU MDR + IMDRF GHTF model; IVDs classified under separate framework substantively aligned with EU IVDR.
• Pakistani Authorised Representative — Pakistan-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + DRAP regulatory interface.
• ISO 13485:2016 — recognised by DRAP as QMS evidence framework; substantial Pakistani-domestic manufacturer ISO 13485 capacity.
• Reliance pathways — DRAP accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan + Chinese + Indian + Turkish + Korean-approval evidence as supporting evidence; CE Mark + FDA 510(k) substantially central; Chinese substantial given CPEC operational context.
• Post-market vigilance — DRAP operates medical-device adverse-event reporting; reporting timelines substantively aligned with EU MDR + IMDRF Adverse Event Reporting Codes.
• IVD Reactivigilance — DRAP operates IVD reactivigilance reflecting Pakistan's substantial clinical-laboratory infrastructure including Aga Khan University Hospital + private-sector + provincial public-health laboratory networks.
• Medicated Cosmetic + Cosmetic Notification — medicated cosmetics + cosmetics require DRAP notification + Urdu/English labelling; INCI-aligned ingredient listing + safety substantiation; substantially EU Cosmetics Regulation elements-aligned framework.
• Alternative Medicine Registration — distinctive Unani + Ayurvedic + Homeopathic + Herbal + Biochemic + nutraceutical + health-product registration under Alternative Medicines + Health Products Rules 2014 recognising substantial Pakistani-traditional-medicine heritage.
• Halal Certification — distinctive halal-certification pathway supporting substantial Gulf + Central Asian + Indonesian + Malaysian + Brunei + sub-Saharan African halal-pharmaceutical + halal-cosmetics + halal-medical-device export-market access.
• Substantial Export-Market Support — DRAP provides substantial Pakistani-domestic manufacturer export-market support to SAARC + Gulf + Central Asian + sub-Saharan African + South-East Asian markets via GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product + WHO CPP issuance.

DRAP operates the Pakistan National Pharmacovigilance Centre under the Pharmacovigilance Rules 2022. Pakistan is a WHO Programme for International Drug Monitoring (PIDM) member + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Pakistan National Pharmacovigilance Centre coordinates with Aga Khan University Hospital + Karachi University + Punjab University + Quaid-i-Azam University + COMSATS academic-medical-centres + Pakistan Pharmacists Association + Pakistan Medical Commission + Marketing Authorisation Holders + provincial Health Departments. Pakistani pharmacovigilance is uniquely shaped by substantial regional pharmaceutical-hub status + substantial vaccine surveillance commitments (Pakistan Expanded Programme on Immunization + Gavi-supported campaigns) + substantial counterfeit-medicine quality-risk monitoring + substantial 4-province + 4-territory operational scope.

• Pakistan National Pharmacovigilance Centre — coordinated by DRAP Division of Pharmacovigilance and Clinical Studies.
• WHO PIDM Member — Pakistan contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• Pakistani PV Network — coordinated national network with effector centres in major Pakistani academic-medical-centres (Aga Khan University Hospital + Karachi University + Punjab University + Quaid-i-Azam University + COMSATS + Liaquat National Hospital + Shaukat Khanum Memorial Cancer Hospital + Pakistan Institute of Medical Sciences + provincial public-health structures) + Pakistan Pharmacists Association + Marketing Authorisation Holders.
• ADR Reporting — DRAP operates ADR reporting via Pakistan National Pharmacovigilance Centre portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — DRAP accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market substantively aligned with ICH E2 + WHO PV guidance.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2).
• Risk Management Plans (RMP) — DRAP requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + ATMPs + high-risk products.
• Active surveillance — Pakistan National Pharmacovigilance Centre operates substantial active-surveillance programmes for COVID-19 vaccines + childhood immunisation + biosimilars + high-risk products.
• AEFI Surveillance — Pakistani vaccine adverse-event surveillance aligned with WHO methodology; central to Pakistan Expanded Programme on Immunization + Gavi + UNICEF + WHO-supported immunisation campaigns + substantial polio-eradication programme.
• Matériovigilance + Cosmétovigilance — DRAP operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Counterfeit + substandard medicine surveillance — substantial role given Pakistan's substantial pharmaceutical supply-chain complexity + cross-border Afghan + Iranian + Indian border-trade quality risks.
• PIC/S Mutual-Recognition — substantial PIC/S Member pharmacovigilance + GMP-inspection mutual-recognition.
• Halal-Pharmaceutical Quality Surveillance — distinctive halal-pharmaceutical + halal-cosmetics quality surveillance supporting substantial Gulf + Central Asian + Indonesian + Malaysian + Brunei + sub-Saharan African export-market access.

• PIC/S Member (since 2024) — one of the most operationally significant recent DRAP capability achievements; substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Israel + Argentina + USA-FDA bilateral inspections.
• WHO PIDM Member — Pakistan contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• WHO PQ Programme Participant — Pakistan-manufactured medicines + vaccines + biosimilars via WHO PQ enable substantial UN-agency humanitarian procurement + LMIC market access notably for ARVs + TB medicines + reproductive-health products + vaccines.
• WHO EMRO + WHO SEARO — substantial WHO Eastern Mediterranean + South-East Asia Regional Office cooperation reflecting Pakistan's hybrid regional position.
• ECO Member State — Economic Cooperation Organization (10 Member States — Iran + Türkiye + Pakistan + Afghanistan + Azerbaijan + Kazakhstan + Kyrgyzstan + Tajikistan + Turkmenistan + Uzbekistan); substantial regional ECO pharmaceutical regulatory cooperation.
• SAARC — South Asian Association for Regional Cooperation (8 Member States — Afghanistan + Bangladesh + Bhutan + India + Maldives + Nepal + Pakistan + Sri Lanka); substantial SAARC pharmaceutical regulatory cooperation interest.
• OIC + D-8 — Organisation of Islamic Cooperation + Developing 8 Member State substantial pharmaceutical + halal-pharmaceutical cooperation.
• ICH Observer — substantial ICH guideline implementation in Pakistani regulatory practice including ICH Q1-Q14 + E1-E20 + M1-M11 + S1-S12.
• Chinese NMPA Bilateral — CPEC Belt and Road Initiative substantial bilateral pharmaceutical cooperation + substantial China-Pakistan pharmaceutical + API + medical-device trade.
• Indian CDSCO Bilateral — substantial South Asian SAARC peer cooperation despite political constraints; substantial cross-border pharmaceutical + API trade reality.
• Turkish TİTCK Bilateral — regional ECO + PIC/S Member peer cooperation reflecting Pakistan-Türkiye pharmaceutical-trade + D-8 cooperation.
• Iranian IFDA Bilateral — ECO + regional border peer cooperation reflecting Pakistan-Iran pharmaceutical-trade + cross-border humanitarian operations.
• Afghan MoPH Bilateral — substantial bilateral humanitarian + pharmaceutical-trade cooperation reflecting cross-border refugee + humanitarian operations + ECO peer membership.
• Bangladeshi DGDA + Sri Lankan NMRA Bilateral — SAARC peer cooperation reflecting cross-border pharmaceutical-trade.
• Saudi SFDA + UAE MoHAP + GCC Regulators Bilateral — substantial Gulf-export market cooperation + GHC reliance reflecting Pakistan's substantial Gulf pharmaceutical export-market position.
• UK MHRA + EMA Bilateral — substantial historical UK MHRA + EMA cooperation reflecting Commonwealth + bilateral trade.
• ICDRA + IMDRF + IPRP + IGBA participation — substantial international participation.
• Donor + Bilateral Cooperation — substantial bilateral cooperation with WHO + UNICEF + Gavi + Global Fund + Stop TB Partnership + USAID (historical) + UK FCDO + DFID (historical) + JICA + KOICA + GIZ + World Bank + Asian Development Bank + Islamic Development Bank.

• Drug Pricing Policy 2018 (amended) compliance under-planned — most operationally significant feature of Pakistani pharmaceutical market access; substantial MRP-fixation + Reference Pricing + Hardship Cases + Annual CPI-linked adjustment + Innovative Drug pricing framework frequently under-planned by foreign manufacturers leading to substantial registration delays + post-approval pricing disputes.
• PIC/S Member (since 2024) mutual-recognition under-leveraged — substantial PIC/S Member mutual-recognition (one of the most operationally significant recent DRAP achievements) substantially under-leveraged for GMP-inspection coordination.
• Pakistani Authorised Representative not properly designated — application rejected at DRAP intake or post-approval compliance failure; Pakistani Authorised Representative must be Pakistan-resident legal entity with appropriate licensure.
• Urdu/English labelling deficiencies — Urdu + English required; many applicants provide insufficient Urdu-language patient leaflet content.
• DRAP GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Pakistan-specific DRAP GMP clarifications.
• Pakistan climate-zone stability data missing — Pakistan spans Climate Zone IVa Indo-Gangetic Plain (Lahore + Multan + Faisalabad + Rawalpindi + Peshawar) + IVb arid Thar + Balochistan (Quetta + Sukkur + Gwadar) + monsoon-affected coastal (Karachi + Hyderabad + Gwadar) + Himalayan high-altitude (Northern Areas + AJK + GB); requires substantial zonal-specific stability data.
• Halal Certification not addressed — distinctive halal-certification pathway substantially under-leveraged for substantial Gulf + Central Asian + Indonesian + Malaysian + Brunei + sub-Saharan African halal-pharmaceutical export-market access.
• Alternative-Medicine + Nutraceutical Framework not understood — distinctive Unani + Ayurvedic + Homeopathic + Herbal + Biochemic + nutraceutical + health-product framework under Alternative Medicines + Health Products Rules 2014 substantially misunderstood by foreign manufacturers entering Pakistani health-product market.
• WHO PQ programme opportunity not leveraged — Pakistani-domestic manufacturers can leverage substantial WHO PQ programme participation for UN-agency humanitarian procurement + LMIC market access notably for ARVs + TB medicines + reproductive-health products + vaccines.
• EMA + SRA + WHO PQ reliance under-utilised — substantial EMA + Stringent Regulatory Authority + WHO PQ reliance substantially under-utilised.
• CPEC + Belt and Road pharmaceutical + API + medical-device trade opportunity not leveraged — substantial China-Pakistan Economic Corridor pharmaceutical + API + medical-device trade growth substantially under-leveraged.
• Gulf-export market opportunity not leveraged — substantial Pakistan-Gulf pharmaceutical export-market opportunity (Saudi Arabia + UAE + Qatar + Oman + Bahrain + Kuwait + Iraq + Yemen) substantially under-leveraged via DRAP-SFDA + DRAP-MoHAP + DRAP-GCC bilateral arrangements + GHC reliance.
• Bioequivalence centres + biowaiver — DRAP BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• Counterfeit + substandard medicine quality risks under-monitored — Pakistan's substantial pharmaceutical supply-chain complexity + cross-border Afghan + Iranian + Indian border-trade smuggling create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance.
• Substantial Pakistani export-market support not leveraged — substantial DRAP GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product + WHO CPP capacity substantially under-leveraged for foreign-manufacturer Pakistani-localised production + SAARC + Gulf + Central Asian + sub-Saharan African + South-East Asian export markets reaching ~USD 350+ million annual export value.
• Substantial Pakistani academic-medical-centre clinical-research capacity not leveraged — substantial Aga Khan University + Karachi University + Punjab University + Quaid-i-Azam University + COMSATS + 241-million-population clinical-research capacity substantially under-leveraged.
• Variations strategy not planned — variations procedure with Pakistan-specific timelines + fee structure.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.

V5 Ultimate provides the operational infrastructure Pakistani + foreign-supplier sites need for the DRAP Act 2012 + Drugs Act 1976 + Pakistan Pharmacy Act 1967 + DRAP General Rules + DRAP GMP + Medical Devices Rules 2017 + Biological Drugs Rules 2022 + Pharmacovigilance Rules 2022 + Alternative Medicines + Health Products Rules 2014 + Drug Pricing Policy 2018 (amended) + PIC/S Member mutual-recognition + WHO PQ programme participation + WHO EMRO + WHO SEARO + ECO + SAARC + OIC + D-8 + Pakistan National Pharmacovigilance Centre + substantial Pakistani-domestic manufacturer export-market support to SAARC + Gulf + Central Asian + sub-Saharan African + South-East Asian markets + substantial CPEC + Belt and Road operational support + substantial halal-pharmaceutical certification support.

• DRAP GMP control framework — PIC/S + ICH Q7 + WHO TRS 986 Annex 2 + EU GMP elements-aligned controls with ALCOA+ data-integrity + Pakistan-specific clarifications + Climate Zone IVa Indo-Gangetic Plain + IVb arid Thar + Balochistan + monsoon-affected coastal + Himalayan high-altitude stability monitoring.
• DRAP registration dossier packaging — Pakistan CTD-aligned dossier structure with Pakistan Module 1 specifics + Module 3 stability + Urdu/English patient leaflet + Pakistani Authorised Representative declarations + DRAP General Rules framework + substantial EU Module reuse.
• Drug Pricing Policy 2018 (amended) compliance workflow — most operationally significant feature; substantial MRP-fixation + Reference Pricing + Hardship Cases + Annual CPI-linked adjustment + Innovative Drug pricing packaging.
• PIC/S Member mutual-recognition workflow — substantial PIC/S Member (since 2024) mutual-recognition packaging for GMP-inspection coordination.
• WHO PQ programme workflow — Pakistani-manufactured medicines + vaccines + biosimilars WHO PQ submission packaging for substantial UN-agency humanitarian procurement + LMIC market access notably for ARVs + TB medicines + reproductive-health products + vaccines.
• EMA + SRA + WHO PQ reliance workflow — DRAP-EMA + DRAP-FDA + DRAP-Health Canada + TGA + Swissmedic + MHRA + MFDS + PMDA + WHO PQ reliance packaging.
• CPEC + Belt and Road workflow — substantial China-Pakistan Economic Corridor pharmaceutical + API + medical-device trade packaging.
• Halal-pharmaceutical + halal-cosmetics certification workflow — distinctive Pakistan Halal Authority + provincial Halal Authorities + PSQCA coordination packaging supporting substantial Gulf + Central Asian + Indonesian + Malaysian + Brunei + sub-Saharan African halal-pharmaceutical export-market access.
• Pakistani Authorised Representative workflow — foreign-manufacturer Pakistani Authorised Representative designation + role-management + Pakistan-specific post-market surveillance.
• Pakistani clinical-trial workflow — DRAP CTA + Aga Khan University + Karachi University + Punjab University + Quaid-i-Azam University + COMSATS / Pakistan Institute of Medical Sciences / Shaukat Khanum Memorial Cancer Hospital Ethics Committee + IRB coordination + Pakistani SUSAR reporting via Pakistan National Pharmacovigilance Centre.
• Pakistan National Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Pakistani ICSR + Pakistani PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + substantial polio-eradication + EPI surveillance support.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
• Medical-device + IVD + cosmetic + alternative-medicine + nutraceutical + health-product workflow — DRAP frameworks dossier packaging + Class A-D classification + ISO 13485 + Pakistani Authorised Representative + post-market vigilance + distinctive Unani + Ayurvedic + Homeopathic + Herbal + Biochemic frameworks.
• Counterfeit + substandard medicine surveillance workflow — Pakistan's substantial pharmaceutical supply-chain complexity + cross-border Afghan + Iranian + Indian border-trade quality-risk monitoring + WHO Global Surveillance & Monitoring System integration.
• Biosimilar + vaccine workflow — DRAP biosimilar + vaccine registration packaging substantively aligned with EMA + WHO PQ frameworks; substantial NIH Islamabad + private-sector vaccine-manufacturing capacity support.
• Pakistani export-market support workflow — substantial DRAP GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product + WHO CPP capacity packaging for foreign-manufacturer Pakistani-localised production + SAARC + Gulf + Central Asian + sub-Saharan African + South-East Asian export markets reaching ~USD 350+ million annual export value.
• SAARC + Gulf + Central Asian + CPEC + ECO regional bridging — for companies operating across SAARC + Gulf + Central Asian + CPEC + ECO jurisdictions, V5 surfaces DRAP + India CDSCO + Bangladesh DGDA + Sri Lanka NMRA + Saudi SFDA + UAE MoHAP + GCC + Türkiye TİTCK + Iran IFDA + Afghan MoPH + Chinese NMPA + Central Asian harmonised dossier-element reuse alongside national-specific extensions.